Stocktoria
Xenon Pharmaceuticals Inc. XENE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-10-17
Xenon Pharmaceuticals Inc. statistics & valuation
Market cap$5.0B
P / B8.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -4974.3% | — | — | -1368.9% | -428.4% |
| Net margin | -4612.1% | — | — | -1328.9% | -427.8% |
| FCF margin | -3732.2% | — | — | -1101.6% | -388.1% |
| Return on assets | -54.6% | -29.4% | -18.9% | -16.6% | -13.8% |
| Return on equity | -59.5% | -31.0% | -19.7% | -17.4% | -14.3% |
| Current ratio | 13.42 | 17.85 | 23.65 | 26.44 | 39.03 |
| Revenue growth | — | — | -100.0% | -48.8% | -42.7% |
Source: SEC EDGAR filings · CIK 0001582313 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.